Equities

Dr Reddy's Laboratories Ltd

Dr Reddy's Laboratories Ltd

Actions
  • Price (EUR)13.50
  • Today's Change0.20 / 1.50%
  • Shares traded0.00
  • 1 Year change+9.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

  • Revenue in USD (TTM)3.55bn
  • Net income in USD631.70m
  • Incorporated1984
  • Employees27.05k
  • Location
    Dr Reddy's Laboratories Ltd8-2-337, Road No.3 Banjara HillsHYDERABAD 500034IndiaIND
  • Phone+91 4 049002900
  • Fax+91 4 049002999
  • Websitehttps://www.drreddys.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
DRREDDY:NSI since
announced
Transaction
value
Menolabs LLCDeal completed11 Dec 202311 Dec 2023Deal completed4.83%3.00m
Data delayed at least 15 minutes, as of Nov 25 2024 10:18 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.